nanoliposomal irinotecan,docetaxel
ipsen,takeda,servier
['net-02', '4005']
 preliminary results of the #net-02 trial presented at #asco2022 indicates manageable toxicity &amp; promising activity of nal-iri/5fu/folinic acid vs #docetaxel in progressive #pd-ep-nec and is proposed for further evaluation in trials abs4005 #meded
Independent and international experts in the field of neuroendocrine tumors (NET). Part of https://t.co/09VX0euMEA